[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413043":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":17,"locations":32,"responsibleParty":44,"collaborators":17,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":17,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":17,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":17,"overallStatus":68,"whyStopped":17,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Applied Science Private University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"n-3FA group","EXPERIMENTAL","Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.",[13],"Dietary Supplement: 300 mg of omega3-FA",{"label":15,"type":16,"description":17,"interventionNames":17},"Control group","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":17},"DIETARY_SUPPLEMENT","300 mg of omega3-FA","The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.",[9],[25,29],{"name":26,"affiliation":27,"role":28},"Mahmoud S Abu-Samak, PhD","Department of Clinical Pharmacy and Therapeutics , Applied Science Private University, Amman -Jordan","STUDY_CHAIR",{"name":30,"affiliation":27,"role":31},"Sara M Daboul, MSC","PRINCIPAL_INVESTIGATOR",[33],{"facility":34,"status":17,"city":35,"state":17,"zip":17,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":17},"Mahmoud S Abu-Samak","Amman","Jordan","JO",{"type":39,"coordinates":40},"Point",[41,42],35.94503,31.95522,{"lat":42,"lon":41},{"type":31,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Mahmoud Suleiman Abu-Samak","Mahmoud S Abu-Samak, PhD Study Principal Investigator Department of Clinical Pharmacy and Therapeutics","100413043","the-effect-of-omega--3-supplements-on-the-serum-levels-of-aceace2-ratio-as-a-potential-key-in-cardiovascular-disease-and-covid-19-a-randomized-clinical-trial-in-the-covid-19-uninfected-jordanian-people-100413043",false,"NCT04658433","The Effect of Omega -3 Supplements on the Serum Levels of ACE\u002FACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People","The Effect of Omega -3 Supplements on the Serum Levels of ACE\u002FACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the COVID-19 Uninfected Jordanian People","Inclusion Criteria:\n\n* Inclusion criteria included males and females in the age range of 35-65 years without a medical diagnosis of COVID-19 infection.\n\nExclusion Criteria:\n\n* Any subject with any chronic disease such as CVD, diabetes, or immune problems, including autoimmune diseases, chronic or severe infections was excluded.\n* Pregnant, breastfeeding, and females using hormonal contraceptives were excluded.",true,"ALL","35 Years","65 Years",{"count":59,"type":60},100,"ACTUAL","INTERVENTIONAL",[63],"NA","The Renin-Angiotensin-Aldosterone System (RAAS) is involved in blood pressure regulation and electrolyte balance. Angiotensin-converting enzyme (ACE) is a critical regulator of RAAS by cleaving angiotensin (Ang1) to Angiotensin2 (Ang2), which is the most powerful biologically active product of RAAS \\[1\\]. In the same context, angiotensin-converting enzyme 2 (ACE2) converts Ang2 to Ang (1-7), which is a vasodilator, antithrombotic, and antihypertrophic peptide \\[2\\]. ACE2 which is found in many tissues \\[3\\] has opposite effects to ACE on the heart, kidneys, and lungs \\[4\\]. Many pathological conditions, in particular cardiovascular disease (CVD), have shown a link between a disturbance in ACE\u002FACE2 ratio and the downregulation of ACE2 levels \\[5\\]. Also, ACE\u002FACE2 has been reported to be higher in moderate to severe chronic heart failure \\[6\\] as well as systolic blood pressure \\[7\\]. Recently, an elevated ACE\u002FACE2 ratio is linked to Coronavirus disease 2019 (COVID-19). SARS-COV2 enters target cells by binding of the spike protein to ACE2 and a specific transmembrane serine protease 2 (TMPRSS2) for the spike (S) protein priming, which also leads to downregulation of ACE2 \\[8\\]. Down-regulation of ACE2 caused by Coronavirus may have a potential role in the pathogenesis of COVID-19 infection. Accordingly, people with a higher ACE\u002FACE2 ratio may be more at increased risk of worse Covid-19 consequences \\[9\\].\n\nOn the other hand, omega-3 fatty acids could decrease CVD risk by their anti-inflammatory anti-thrombotic function \\[10\\]. A meta-analysis comprising 15,806 patients, showed that omega-3 fatty acids associated with a 30% reduction in fatal myocardial infarction and sudden death, in addition to a 20% reduction in overall mortality \\[11\\]. To the best of our knowledge, no clinical trials have evaluated the effect of omega-3 supplementation on serum ACE\u002FACE2 ratio which is recently ascribed as a potential key in 2019 Covid-19 as well as CVD \\[5,9\\].",[66,67],"Cardiovascular Risk Factor","Covid19","COMPLETED","2022-02-23",{"date":71,"type":60},"2022-02-24",{"date":73,"type":60},"2021-03-05",{"date":75,"type":60},"2022-02-10",{"name":5,"class":6},1]